Trials / Not Yet Recruiting
Not Yet RecruitingNCT06156267
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
An Exploratory Study of Neoantigen Personalized mRNA Vaccines in Combination With Adebrelimab and Sequential mFOLFIRINOX Regimen in Patients With Surgically Resected Pancreatic Adenocarcinoma
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected pancreatic adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab | Adebrelimab is a programmed death-ligand 1 antibody. |
| DRUG | mRNA tumor vaccines | neoantigen personalized mRNA vaccines |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2026-04-01
- Completion
- 2027-03-01
- First posted
- 2023-12-05
- Last updated
- 2023-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06156267. Inclusion in this directory is not an endorsement.